| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/01/2002 | US6335371 Administering 1,7,7-trimethylbicyclo(2.2.1)heptane derivative such as deramciclane to treat psychological, anxiety, nervous sytem and aging disorders |
| 01/01/2002 | US6335361 Method of treating benign forgetfulness |
| 01/01/2002 | US6335360 Indoline-2-carboxylic amide derivatives; obesity, eating and psychological disorders |
| 01/01/2002 | US6335358 Lactacystin analogs |
| 01/01/2002 | US6335354 Aminopyridines and methods of using thereof |
| 01/01/2002 | US6335352 Administering heterocyclic cyanoguanidine derivatives as chemokine inhibitors |
| 01/01/2002 | US6335348 Administering pipecolic acid derivative as cognition activator and to treat eye and nervous system disorders |
| 01/01/2002 | US6335346 Pyrrolo-(3,4-b)quinoline derivatives, method for the production and use thereof as a medicament |
| 01/01/2002 | US6335345 Spiro compounds |
| 01/01/2002 | US6335342 Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| 01/01/2002 | US6335334 Hypertensive agents, anticoagulants; cardiovascular and sexual disorders, angina pectoris, and atherosclerosis |
| 01/01/2002 | US6335331 Antihistamines, antiallergens, brochodilator agents and antispasmodic agents |
| 01/01/2002 | US6335328 Process for the isolation of galanthamine |
| 01/01/2002 | US6335327 1-benzazepine derivatives; agonists or antagonists of vasopressin and/or oxytocin |
| 01/01/2002 | US6335326 Dopamine agonist and antagonists; central nervous system and psychological disorders; anxiolytic, antidepressant and antiischemic agents; parkinson*s disease |
| 01/01/2002 | US6335323 Administering to the patient a combination of antidepressant or a monoamine oxidase inhibitor, vitamin b12, and precursor or inducer of a neurotransmitter, e.g. l-phenylalanine |
| 01/01/2002 | US6335180 Nucleic acid sequences encoding capsaicin receptor and uses thereof |
| 01/01/2002 | US6335031 (s)-n-ethyl-3-(1-dimethylamino)ethyl)-n-methyl-phenyl-carbamat salt form and antioxidant; alzheimer's disease therapy |
| 01/01/2002 | US6335021 Composition for controlling mood disorders in healthy individuals |
| 01/01/2002 | US6334998 Estrogens for treating ALS |
| 01/01/2002 | CA2186337C New amino 5,6,7,8-tetrahydronaphtho¬2,3-b|furane and indano¬5,6-b|furane derivatives; process for preparing the same and pharmaceutical compositions containing them |
| 01/01/2002 | CA2056799C 1,4-dihydropyridine derivatives and methods of producing the same |
| 01/01/2002 | CA2051830C Tricyclic heterocycles |
| 01/01/2002 | CA2042473C Piperidino-nmda antagonists |
| 01/01/2002 | CA2010217C Aralkylamine compounds |
| 12/29/2001 | CA2351904A1 Target |
| 12/27/2001 | WO2001098522A2 Positively-charged peptide nucleic acid analogs with improved properties |
| 12/27/2001 | WO2001098490A1 A g-protein coupled receptor |
| 12/27/2001 | WO2001098486A1 Mutation associated with epilepsy |
| 12/27/2001 | WO2001098471A2 Human phosphodiesterases |
| 12/27/2001 | WO2001098442A1 Stress-relieving perfumes and stress-relieving perfume compositions containing the same |
| 12/27/2001 | WO2001098367A2 Neuroactive peptides for treatment of hypoxia and related conditions |
| 12/27/2001 | WO2001098361A2 Agonist anti-trk-c monoclonal antibodies |
| 12/27/2001 | WO2001098360A2 Gp354 nucleic acids and polypeptides |
| 12/27/2001 | WO2001098354A2 Human receptors |
| 12/27/2001 | WO2001098353A2 Secreted proteins |
| 12/27/2001 | WO2001098351A2 G-protein coupled receptors |
| 12/27/2001 | WO2001098347A1 Canine liver cell growth factor |
| 12/27/2001 | WO2001098346A2 Methods and compositions for the treatment of peripheral artery disease |
| 12/27/2001 | WO2001098341A1 Novel polypeptide and its dna |
| 12/27/2001 | WO2001098332A2 Secreted redox proteins |
| 12/27/2001 | WO2001098330A2 A RECOMBINANT CELL LINE EXPRESSING GPCRx11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS |
| 12/27/2001 | WO2001098323A2 G-protein coupled receptors |
| 12/27/2001 | WO2001098300A1 Medicines for the prevention and treatment of neurodegenerative diseases |
| 12/27/2001 | WO2001098299A1 Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| 12/27/2001 | WO2001098298A1 Indole derivatives useful for the treatment of cns disorders |
| 12/27/2001 | WO2001098295A1 Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them |
| 12/27/2001 | WO2001098293A1 Heterocyclic aminoalkyl pyridine derivatives as psychopharmaceuticals |
| 12/27/2001 | WO2001098291A2 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| 12/27/2001 | WO2001098290A2 Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 12/27/2001 | WO2001098289A1 Novel non-psychotropic cannabinoids |
| 12/27/2001 | WO2001098286A1 Nitrosated and nitrosylated taxanes, compositions and methods of use |
| 12/27/2001 | WO2001098280A2 5h-2,3-benzodiazepine antagonists of excitatory amino acid receptors |
| 12/27/2001 | WO2001098279A2 Bis-arylsulfones |
| 12/27/2001 | WO2001098273A1 Novel compounds |
| 12/27/2001 | WO2001098272A1 Novel compounds |
| 12/27/2001 | WO2001098271A1 4-substituted piperidine compound |
| 12/27/2001 | WO2001098267A1 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity |
| 12/27/2001 | WO2001098266A2 N-and o-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating cns disorders therewith |
| 12/27/2001 | WO2001098265A2 Process for isolating enantiomers of racemic cetamine |
| 12/27/2001 | WO2001098262A1 Amidine derivatives as selective antagonists of nmda receptors |
| 12/27/2001 | WO2001098256A1 Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones |
| 12/27/2001 | WO2001098253A2 1-amino-alkylcyclohexanes as 5-ht3 and neuronal nicotinicreceptor antagonists |
| 12/27/2001 | WO2001098251A1 Novel substituted nitrocatechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them |
| 12/27/2001 | WO2001098250A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them |
| 12/27/2001 | WO2001097846A1 Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| 12/27/2001 | WO2001097837A1 Solubilised protein vaccines |
| 12/27/2001 | WO2001097813A2 Highly concentrated stable meloxicam solutions |
| 12/27/2001 | WO2001097809A2 Method of treating cardiovascular disease using rapamycin |
| 12/27/2001 | WO2001097807A1 New use of angiotensin ii antagonists |
| 12/27/2001 | WO2001097795A2 Systems and methods for treating a mucosal surface |
| 12/27/2001 | WO2001097793A2 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury |
| 12/27/2001 | WO2001097787A2 Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl) |
| 12/27/2001 | WO2001097786A2 Benzothiazole derivatives |
| 12/27/2001 | WO2001097785A2 Basic copolymers for the treatment of prion-related-disease |
| 12/27/2001 | WO2001097782A1 Stable gabapentin having ph within a controlled range |
| 12/27/2001 | WO2001097780A2 Pharmaceutical compositions comprising an opioid analgesic |
| 12/27/2001 | WO2001097779A2 Improved injectable dispersions of propofol |
| 12/27/2001 | WO2001097751A2 New formulation comprising a betablocker and optionally a cholesterol-lowering agent |
| 12/27/2001 | WO2001097607A2 Transgenic animal model of neurodegenerative disorders |
| 12/27/2001 | WO2001085719A9 Ortho-substituted anthranilic acid amides and their use as medicaments |
| 12/27/2001 | WO2001070967A3 Regulation of human serotonin-like g protein-coupled receptor |
| 12/27/2001 | WO2001064645A3 Derivatives of quinoline as alpha-2 antagonists |
| 12/27/2001 | WO2001060349B1 Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof. |
| 12/27/2001 | WO2001057042A3 4-pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy |
| 12/27/2001 | WO2001053505A3 Herpes virus strains for gene therapy |
| 12/27/2001 | WO2001049711A3 Nucleic acids encoding (poly)peptides having chips activity |
| 12/27/2001 | WO2001047877A3 Process for the preparation of pure citalopram |
| 12/27/2001 | WO2001046700A3 Sodium channels as targets for amyloid beta |
| 12/27/2001 | WO2001046256A3 Vesicle trafficking proteins |
| 12/27/2001 | WO2001045483A3 Method for the preparation of pure citalopram |
| 12/27/2001 | WO2001041771A3 Transdermal system containing acetylsalicylic acid for treatment of migraine |
| 12/27/2001 | WO2001037813A3 Multilayer preparation for a controlled, pulsed release of active substances |
| 12/27/2001 | WO2001034614A3 Compositions and methods for double-targeting virus infections and targeting cancer cells |
| 12/27/2001 | WO2001032646A3 Sulfonamide derivatives |
| 12/27/2001 | WO2001023390A3 Azepinoindole derivatives, the production and use thereof |
| 12/27/2001 | WO2000064485A3 Specifically targeted catalytic antagonists and uses thereof |
| 12/27/2001 | US20010056121 By administering rosemary or sage extracts; carnosic acid, carnosol |
| 12/27/2001 | US20010056119 Materials and methods for the treatment of depression |
| 12/27/2001 | US20010056103 Non-immunosuppressive, piperidino or pyrrolidino amide derivative has an affinity for an FKBP-type immunophilin, useful for treating Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, amyotrophic lateral sclerosis |